PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
3127037-5	1988	The origin of soluble tyrosinase and its utility to employ that enzymatic activity in melanoma chemotherapy using catechols as tyrosinase-dependent precursors of cytotoxic quinones is discussed.	Quinones	172-180	tyrosinase	Mus musculus	22-32	
31585271-7	2019	The UV-visible spectra showed compound 22 inhibits the formation of dopamine quinone, further the molecular docking analysis of compound 22 with tyrosinase (PDB: 2Y9X) indicated that compound 22 interacted with the amino acid residues of tyrosinase.	Quinones	77-84	tyrosinase	Mus musculus	145-155	
31585271-7	2019	The UV-visible spectra showed compound 22 inhibits the formation of dopamine quinone, further the molecular docking analysis of compound 22 with tyrosinase (PDB: 2Y9X) indicated that compound 22 interacted with the amino acid residues of tyrosinase.	Quinones	77-84	tyrosinase	Mus musculus	238-248	
1997095-5	1991	As a possible mechanism that might account for this action, it may be that 4-S-CAP is oxidised by tyrosinase to the o-quinone form via the catechol derivative and that some of the quinones then conjugate with sulfhydryl enzymes including DNA polymerase, thus exerting a killing activity for pigmented melanoma cells.	Quinones	180-188	tyrosinase	Mus musculus	98-108	
3127037-5	1988	The origin of soluble tyrosinase and its utility to employ that enzymatic activity in melanoma chemotherapy using catechols as tyrosinase-dependent precursors of cytotoxic quinones is discussed.	Quinones	172-180	tyrosinase	Mus musculus	127-137